Distal Left Main Coronary Disease Is a Major Predictor of Outcome in Patients Undergoing Percutaneous Intervention in the Drug-Eluting Stent Era
An Integrated Clinical and Angiographic Analysis Based on the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (T-SEARCH) Registries
Marco Valgimigli, MD,
Patrizia Malagutti, MD,
Gaston A. Rodriguez-Granillo, MD,
Héctor M. Garcia-Garcia, MD,
Jawed Polad, MBChB, MRCP,
Keiichi Tsuchida, MD, PhD,
Evelyn Regar, MD, PhD,
Willem J. Van der Giessen, MD, PhD,
Peter de Jaegere, MD, PhD,
Pim De Feyter, MD, PhD and
Patrick W. Serruys, MD, PhD*
Erasmus Medical Center, Thoraxcenter, Rotterdam, the Netherlands.
View larger version (20K):
[in a new window]
|
Figure 1 Adverse events in patients treated for distal left main coronary artery (LMCA) disease (DLMD) as compared with patients treated for nondistal LMCA disease (NDLMD). Cumulative risk of major adverse cardiac events (MACE) (A) and target vessel revascularization (TVR) (B) in the whole population, and cumulative risk of MACE (C) and TVR (D) in the elective population.
|
|
|
p = 0.048; 
p = 0.066. Abbreviations as in Figure 1.